Distinctive and synergistic signaling of human adenosine A2a and dopamine D2L receptors in CHO cells

Journal of Receptors and Signal Transduction

Volumn 25, Issue 3, 2005, Pages 159-179

  Tang, Yuting ^a   Demarest, Keith T ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

galactosidase reporter gene; Adenosine A2a receptor; Adenylate cyclase; Desensitization; Dopamine D2 receptor; G protein coupled receptor (GPCR); Heterologous sensitization; Homogeneous time resolved fluorescence

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENYLATE CYCLASE; BETA GALACTOSIDASE; DOPAMINE 2 RECEPTOR; DOPAMINE 2L RECEPTOR; G PROTEIN COUPLED RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; QUINPIROLE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ANIMAL CELL; ARTICLE; BASAL GANGLION; CHO CELL; DESENSITIZATION; DOPAMINERGIC TRANSMISSION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; NERVE FUNCTION; NONHUMAN; PARACRINE SIGNALING; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REPORTER GENE;

ADENOSINE; ADENYLATE CYCLASE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BETA-GALACTOSIDASE; BRAIN; CELL LINE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; NEURONS; PERTUSSIS TOXIN; PHENETHYLAMINES; PLASMIDS; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; SPECTROMETRY, FLUORESCENCE; TIME FACTORS; TRANSFECTION;

EID: 26444521662     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890500210487     Document Type: Article

References (52)

1. Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, Reppert SM. Molecular cloning of the rat A2 adenosine receptor: Selective co-expression with D2 dopamine receptors in rat striatum. Brain Res 1992, 14, 186-195.
2. Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 1991, 130, 177-181.
3. Pollack AE, Fink JS. Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 1995, 68, 721-728.
4. Jin S, Johansson B, Fredholm BB. Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J Pharmacol Exp Ther 1993, 267, 801-808.
5. Corsi C, Melani A, Bianchi L, Pepeu G, Pedata F. Effect of adenosine A2A receptor stimulation on GABA release from the striatum of young and aged rats in vivo. Neuroreport 1999, 10, 3933-3937.
6. Mayfield RD, Larson G, Orona RA, Zahniser NR. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: Evidence for an A2a/D2 receptor interaction in globus pallidus. Synapse (NY) 1996, 22, 132-138.
7. Zahniser NR, Simosky JK, Mayfield RD, Negri CA, Hanania T, Larson GA, Kelly MA, Grandy DK, Rubinstein M, Low MJ, Fredholm BB. Functional uncoupling of adenosine A(2A) receptors and reduced responseto caffeine in mice lacking dopamine D2 receptors. J Neurosci 2004, 20, 5949-5957.
8. Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 2000, 20, 5848-5852.
9. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ, Ongini E, Schwarzschild, MA. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 2001, 98, 1970-1975.
10. Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E, Impagnatiello F, Schwarzschild MA, Chen J-F. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002, 22, 1054-1062.
11. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Jr., Schwarzschild, MA. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001, 21, RC143.
12. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999, 52, 1673-1677.
13. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002, 80, 262-270.
14. Ongini E, Monopoli A, Impagnatiello F, Fredduzzi S, Schwarzschild M, Chen J-F. Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes. Drug Dev Res 2001, 52, 379-386.
15. Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 1991, 88, 7238-7241.
16. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluis C, Franco R, Ferre S, Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002, 277, 18091-18097.
17. Kudlacek O, Just H, Korkhov VM, Vartian N, Klinger M, Pankevych H, Yang Q, Nanoff C, Freissmuth M, Boehm S. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology 2003, 28, 1317-1327.
18. Vortherms TA, Watts VJ. Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation. J Pharmacol Exp Ther 2004, 308, 221-227.
19. Canals M, Marcellino D, Fanelli F, Ciruela F, De Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, Ferre S, Lluis C, Bouvier M, Franco R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 2003, 278, 46741-46749.
20. Kamiya T, Saitoh O, Yoshioka K, Nakata H. Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem Biophys Res Commun 2003, 306, 544-549.
21. Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, Fredholm BB, Nairn AC, Greengard P, Fisone G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature (Lond) 2002, 418, 774-778.
22. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard, P. Diverse Psychotomimetics act through a common signaling pathway. Science 2003, 302, 1412-1415.
23. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, Fisone G. Regulation of the phosphorylation of the dopamine-and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, adenosine A2A receptors. Proc Natl Acad Sci USA 2000, 97, 1856-1860.
24. Tang Y, Luo J, Fleming CR, Kong Y, Olini GC, Wildey MJ, Cavender DE, Demarest KT. Development of a sensitive and HTS-compatible reporter gene assay for functional anal, of human adenosine A2a receptors in CHO-K1 cells. Assay Drug Dev Techn 2004, 2, 281-289.
25. Malmberg A, Mohell N. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: Effects of ions and guanine nucleotides. J Pharmacol Exp Ther 2005, 274, 790-797.
26. Chen W, Shields TS, Stork PJ, Cone RD. A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways. Anal Biochem 1995, 226, 349-354.
27. Klotz KN. Adenosine receptors and their ligands. N-S Arch Pharmacol 2000, 362, 382-391.
28. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 1998, 273, 18677-18680.
29. Jang IS, Juhnn YS. Adaptation of cAMP signaling system in SH-SY5Y neuroblastoma cells following expression of a constitutively active stimulatory G protein alpha, Q227L Gsalpha. Exp Mol Med 2001, 33, 37-45.
30. Sunahara RK, Dessauer CW, Gilman AG. Complexity and diversity of mammalian adenylyl cyclases. Ann Rev Pharmacol 1996, 36, 461-480.
31. Watts VJ. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J Pharmacol Exp Ther 2002, 302, 1-7.
32. Salim H, Ferre S, Dalal A, Peterfreund RA, Fuxe K, Vincent JD, Lledo PM. Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells. J Neurochem 2000, 74, 432-439.
33. Palmer TM, Gettys TW, Jacobson KA, Stiles GL. Desensitization of the canine A2a adenosine receptor: Delineation of multiple processes. Mol Pharmacol 1994, 45, 1082-1094.
34. Mundell SJ, Kelly E. Evidence for co-expression and desensitization of A2a and A2b adenosine receptors in NG108-15 cells. Biochem Pharmacol 1998, 55, 595-603.
35. Ng GY, Varghese G, Chung HT, Trogadis J, Seeman P, O'Dowd BF, George SR. Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells. Endocrinology 1997, 138, 4199-4206.
36. Mundell SJ, Benovic JL, Kelly EA. dominant negative mutant of the G protein-coupled receptor kinase 2 selectively attenuates adenosine A2 receptor desensitization. Mol Pharmacol 1997, 51, 991-998.
37. Standaert DG, Young AB. Treatment of central nervous system degenerative diseases. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996, 503-519.
38. Sharma SK, Klee WA, Nirenberg M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad Sci USA 1975, 72, 3092-3096.
39. Avidor-Reiss T, Nevo I, Saya D, Bayewitch M, Vogel Z. Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J Biol Chem 1997, 272, 5040-5047.
40. Nevo I, Avidor-Reiss T, Levy R, Bayewitch M, Vogel Z. Acute and chronic activation of the mu-opioid receptor with the endogenous ligand endomorphin differentially regulates adenylyl cyclase isozymes. Neuropharmacology 2000, 39, 364-371.
41. Thomas JM, Hoffman BB. Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: Role of beta gamma subunits in transducing enhanced activity of the type VI isoform. Mol Pharmacol 1998, 49, 907-914.
42. Ammer H, Schulz, R. Enhanced stimulatory adenylyl cyclase signaling during opioid dependence is associated with a reduction in palmitoylated Gs alpha. Mol Pharmacol 1997, 52, 993-999.
43. Toki S, Donati RJ, Rasenick MM. Treatment of C6 glioma cells and rats with antidepressant drugs increases the detergent extraction of G(s alpha) from plasma membrane. J Neurochem 1999, 73, 1114-1120.
44. Vortherms TA, Nguyen CH, Berlot CH, Watts VJ. Using molecular tools to dissect the role of Galphas in sensitization of AC1. Mol Pharmacol 2004, 66, 1617-1624.
45. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z. Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. J Biol Chem 1996, 271, 21309-21315.
46. Rhee MH, Nevo I, Avidor-Reiss T, Levy R, Vogel Z. Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor. Mol Pharmacol 2000, 57, 746-752.
47. Sato M, Gettys Thomas W, Lanier Stephen M. AGS3 and signal integration by Galpha(s)- and Galpha(i)-coupled receptors: AGS3 blocks the sensitization of adenylyl cyclase following prolonged stimulation of a Galpha(i)-coupled receptor by influencing processing of Galpha(i). J Biol Chem 2004, 279, 13375-13382.
48. Johnston CA, Beazely MA, Vancura AF, Wang, JKT, Watts VJ. Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells. J Neurochem 2002, 82, 1087-1096.
49. Glatt CE, Snyder SH. Cloning and expression of an adenylyl cyclase localized to the corpus striatum. Nature 1993, 361, 536-538.
50. Hanoune J, Pouille Y, Tzavara E, Shen T, Lipskaya L, Miyamoto N, Suzuki Y, Defer N. Adenylyl cyclases: Structure, regulation and function in an enzyme superfamily. Mol Cell Endocrinol 1997, 128, 179-194.
51. Lee K-W, Hong J-H, Choi IY, Che Y, Lee J-K, Yang S-D, Song C-W, Kang HS, Lee J-H, Noh JS, Shin H-S, Han P-L. Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J Neurosci 2002, 22, 7931-7940.
52. Kanda T, Jackson MJ, Smith LA, Pearce, RKB, Nakamura J, Kase H, Kuwana Y, Jenner P. Combined use of the adenosine A2A antagonist KW-6002 with 1-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000, 162, 321-327.